Preliminary Observations Using Canine Parvovirus-Specific Transfer Factor in
the Prevention of Canine Parvovirus Disease
We studied the use of specific transfer factor as a modulator of the immune system, with special respect to its effectiveness in the improvement of antibody production and serum biochemical indexes. A total of 21 adult male Beagle dogs were assigned randomly into 3 test groups. After immunized with a multivalent vaccine, dogs in two groups were fed with different dosages of canine parvovirus-specific transfer factor oral liquid products. Laboratory tests to assess the immune profile of experimental animals were performed till 27 days after initial treatment. Present results showed that dogs in the two groups treated with transfer factor products after vaccination had better antibody responses. Dogs receiving larger amount of transfer factor products exhibited more favorable serum biochemical parameters. Transfer factor could also promote growth significantly. The fact that specific antibody level rose and maintained for longer time in the transfer factor treated groups confirmed the immunomodulating properties of transfer factor. We concluded that transfer factor could enhance immunal response to vaccines, modify biochemical indexes in blood serum, decrease the response caused by stress and improve the health of dogs.
Canine parvovirus is a highly virulent pathogen that infects domestic dogs worldwide and responsible for clinical problems of neonates and pregnant bitches (Ohshima et al., 2004). The virus may infect the hearts of neonatal puppies causing myocarditis and cause gastroenteritis in older animals with high mortality. Since, it is especially a risk to puppies that are less than 6 months old, initial and follow-up vaccination is always considered critical to prevent CPV.
Transfer Factor (TF), a dialyzable moiety extracted from immune lymphocytes, is an important antiviral agent and has been successfully used for the treatment of many diseases with satisfactory results, such as primary immunodeficiencies, viral infections and tumor diseases (Prasad et al., 1996; Pizza et al., 1996a, b; Neequaye et al., 1990; Tarkkanen et al., 1981; Vera et al., 1979). Although, the mechanism of these phenomenons is not fully elucidated, these observations corroborate the contention that the TF dialysate is a multifaceted activity product. It proves to be an effective therapeutic reagent and can restore the immune functions and achieve clinical improvement.
In this study we investigated the efficacy of CPV-specific transfer factor
in increasing the immune response of dogs receiving yearly booster of vaccinations.
TF was produced following standard methods, i.e., by animal immunization and
subsequent replication in tissue culture. Specific antibody and serum biochemical
parameters that related to immune response and metabolism were monitored after
the initial vaccination. We are convinced that this specific TF-based immunotherapy
can enhance antibody responses to vaccine and increased resistance to infection.
MATERIALS AND METHODS
Animals and Experimental Design
A total of 12 male Beagle dogs of 3-5 years old were approvaled to be used
in this study by the Beagle Dog Experiment Base in Yangzhou University, Jiangsu
Province, China. All were assessed as healthy before inclusion in the study
based on physical examination and blood values within reference ranges for this
species. Briefly, blood biochemical indexes included glucose (GLU), alkaline
phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase
(AST), lactate dehydrogenase (LDH), creatine kinase (CK), total cholesterol
(TCH), triglyceride (TG), total protein (TP), albumin (ALB), globulin (GLOB),
serum total bilirubin(Tbil), blood urea nitrogen (BUN) creatinine (CREA) and
uric acid (URIC). They were assigned equally into 3 groups and each kept individually
in a disinfectant cage (0.8mx1.0x1.0 m), 0.5 m above the cement ground. They
were fed with commercial extruded pellets (registered trade marker, Naughty
Baby) twice daily with 300 g diets each time, one in the morning and the other
in the evening. Water was supplied by automatic drinkers. Canine parvovirus
(CPV)-specific TF oral liquid products were provided by Shanghai Academy of
Agricultural Sciences. Investigated dogs were immunized with a multivalent vaccine,
including live attenuated canine parvovirus, rabies virus, distemper virus,
parainfluenza virus, infectious canine hepatitis virus. Dogs in group A were
set as a control group. Dogs in group B and group C received 5 and 10 mL TF
oral liquid products, respectively, every other day after vaccination.
Blood samples (3 mL) were collected from the brachial vein in fasting condition
on days 7, 11, 15, 19, 23 and 27 after inoculation. They were kept at 4°C
overnight to allow the whole blood to clot and the fibrin to retract. Sera were
obtained after centrifugation at 4,000x g for 10 min. They were stored at -70°C
and used to evaluate specific antibody response to CPV. The body weight of each
dog was also recorded before each blood sampling.
Preparation of 1% Suspension of Porcine Red Blood Cells
The 3.8% sodium citrate was used as the anticoagulant. Fresh porcine whole
blood was mixed with twice volume of normal saline and centrifuged at 4000x
g for 10 min at room temperature. The supernatant was discarded and precipitated
erythrocytes were washed twice with normal saline as described above. Red cells
deposition was diluted 1:99 with normal saline.
Hemagglutination-Inhibition (HI) Test
The antigen used in this test was Canine Parvovirus (CPV), donated by Professor
Houda Li in College of Veterinary Medicine, Yangzhou University, China. HI test
was conducted by the conventional microtiter method as previously described
(Mathys et al., 1983) and the β method (i.e., variable antibody
titer and constant virus concentration) was used. Equal aliquots of sera were
pooled from 7 dogs of each group. Each serum sample was assayed in triplicate
and the titer was expressed as the highest antibody dilution inhibiting 4 hemagglutination
units of virus. Briefly, two-fold serial dilution of 25 μL sample serum
was made with normal saline in U bottom microtiter plate (Nunc). Twenty five
microliter CPV antigen suspension, pre-titrated by Hemagglutination (HA) test
and contained 4 HA unit virus, was added into each well and allowed to stand
at room temperature for 60 min to facilitate antigen antibody reaction. Twenty
five microliter of 1% porcine red blood cell suspension was added into each
well and again allowed to stand at room temperature for another 30 min. Positive
and negative controls were run simultaneously with the test samples to validate
Determination of Biochemical Indexes in Serum
Conventional biochemical indexes were determined on days 1, 5, 9, 13, 17
and 21 after inoculation. Plasma glucose (GLU) was determined by the glucose
oxidase method (kits for glucose oxidase-peroxidase terminal calorimetric analysis,
Shanghai Rongsheng Biotechnology Co., Ltd.). Total Protein (TP) was assayed
by biuret calorimetric assay. Conventional serum biochemical markers, concentrations
of serum albumin (ALB), globulin (GLOB), total cholesterol (TCH) and triglyceride
(TG) were measured by automatic biochemical analyzer (HITACHI 7170S, Japan).
Statistical analysis were performed using the one-way ANOVA procedure of
SAS (SAS Inst., Inc., Cary, NC). When a statistical significance was detected
(p<0.05), comparisons between means were carried out using the Least Significant
Evaluation of HI Activity
Compared with vaccinated dogs in group A, animals treated with TF products
post immunization elicited a much better antibody response. The dogs in group
B and group C always had higher antibody titres to CPV than did animals in group
A (Fig. 1 ). At the end of the experiment, dogs in group C
still maintained a higher antibody titre (109) than animals in group
|| Changes in antibody titres in immunized dogs
||Comparisons of body weight between dogs in different groups.
Columns with different letter on the top had a significant level of p<0.05
Present results indicated that CPV-specific TF oral products, fed to animals
after inoculation of vaccines, helped to maintain the antibody titre at a relatively
high level and this effect of TF was revealed to be dose related.
Effects of TF on the Body Weight
Experimentally immunized dogs in group C, which received immunization in
association with large amount of TF oral products, always had significantly
higher body weight than animals in other groups (Fig. 2).
It was demonstrated that TF had a significant effect on growth promotion and
this effect was proportional to the dose, which was consistent with our above
Effects of TF on Serum Biochemical Markers Plasma Glucose
A decrease of plasma glucose concentration was observed in all tested animals
5 days after inoculation (Fig. 3). This stage was consistent
with the time when antibody was actively synthesized by organism and more nutrients
were decomposed. While dogs in group C showed a continual increase in plasma
glucose concentration, the second decrease of glucose content was detected in
animals from other groups 17 days after inoculation. At this specific stage,
a significantly higher glucose concentration was kept by dogs in group C (3.44±0.58
mmol L-1) than animals did in group A (2.25±0.91 mmol L-1)
and group B (2.54±0.29 mmol L-1). This higher level of glucose
content was maintained till 21 days after inoculation, although, not reaching
the statistical significant level. We noticed that when group B was compared
with group A, concentrations of plasma glucose followed similar changes with
time. However, glucose concentration of group C varied in a different way which
indicated a more vigorous metabolism and was evidently induced by intake of
more TF oral products.
Serum TP, ALB and GLOB
No significant differences were observed in the concentrations of serum
TP, ALB and GLOB in all tested animals from different groups. When serum TP
and ALB contents were considered, indexes in group C fluctuated more gently
than that in group B and group A.
||Variations of average plasma glucose concentration in tested
groups. Values with different small and capital letters meant significant
difference of 0.05 and 0.01, respectively
||The ratios of serum albumin/total protein in different groups.
Columns with ** on the top had a significant level (p<0.01)
The ranges of variation in group A, B and C were 10.3, 7.38 and 7.00 g L-1
for TP content and 4.07, 4.04 and 2.07 g L-1 for ALB content, respectively.
Furthermore, we found out that GLOB concentrations in group C and group B exhibited
larger scopes of variation than that in group A (6.87, 6.52 and 6.06 g L-1,
respectively). Since, immunoglobins accounted for the large part of serum globulins,
we assumed it to be the result of promoted differentiation of plasmacytes induced
by TF oral products. When the ratio of serum ALB/TP were compared among different
groups, dogs in group C always had relatively higher values than animals in
the other two groups (Fig. 4), which confirmed that TF products
did improve the immunity of the organism and this effect could be observed only
at a relatively higher TF intake.
||Comparisons of serum TG and TCH contents in different groups.
Columns with * on the top had a significant level (p<0.05)
Serum TG and TCH
When serum TG and TCH contents were evaluated, dogs in group B had almost
the same values as that in group A. However, animals in group C always had relatively
higher values than that in group A except the TG content detected on first day
after inoculation (Fig. 5). Dogs in group B and C received
similar treatments after inoculation. This difference could be attributed only
to the different dosage of TF products received. Present results demonstrated
that TF promoted the absorption of nutritional elements in the diet. As we know
serum albumin played an important role in lipid transportation, the results
were consistent with the facts that animals in group C had a relatively higher
ratio of ALB/TP.
Canine parvovirus, continuing to evolve and giving rise to new antigenic types and virus mutants that spread through the dog population (Truyen, 2006) is becoming more and more clinically and epidemiologically significant. Since, its first isolation in 1978 (Appel et al., 1979) a number of mutants have been described (Parrish et al., 1985, 1988; Truyen, 1999; Ikeda et al., 2002; Martella et al., 2004). They not only showed antigenic differences but also differed in their reactivity in virus neutralization tests. These differences explained the variation in the minimum protective titre that young animals relied on to defense against virus infection. Up to now, vaccination was successful in transforming the CPV pandemic into a well-controlled situation. They are potent to prevent disease and even infection in most cases. However, most of the currently used vaccines are modified live virus vaccines based on the original virus type. They do not contain the newest antigenic types which imply incomplete protection for the animals. The fact is that there are still many cases of clinical parvovirus in dogs, especially puppies with decreasing level of maternal antibodies. There is a potential need to increase the protective effect of currently used vaccines. In order to increase the potency of traditional vaccine we used CPV-specific TF associated with vaccination to ascertain measurable clinical advantage in the prevention of CPV disease.
Although, the precise chemical nature and the exact mode of action are not fully understood, TF has in many studies proved its efficacy in treating viral infections without any adverse side effects or drawbacks, even when it is used for long-term treatments and in injectable form (Fujisawa et al., 1984; Corbeel et al.,1984; Neequaye et al., 1990; Pizza et al., 1994; Byston et al., 1996; Levine, 1996; Dvoroznáková et al., 2009). It is an ideal therapeutic agent in increasing the immune response of the organism and reducing the frequency and the severity of diseases.
The present study demonstrated the efficacy of TF in increasing the antibody response. As we know TF, a complex group of many low-molecular-weight proteins, can not only transfer specific immunity from an immune donor to a recipient but also have immune modulating activities (Kirkpatrick, 1996). Present results collaborate with the findings of other investigators. The immunomodulative effect of TF emerged gradually after a stagnation of antibody development. Present study suggested that TF had a positive effect on the host humoral immune response against the infection of CPV, which was beneficial for its resistance against viral pathogen. Meanwhile, a relatively higher body weight was observed in dogs received larger amount of TF, an increase in serum content of glucose was associated with this favorable growth rate. One of the possible reasons was that more nutrients intake were transformed into glucose under the condition of increased digestibility, which facilitated their transportation and further storage in the form of liver glycogen or muscle glycogen and helped to improve the general body defense.
The total protein in serum, coming from synthesis in liver and intestinal absorption, plays an important role in organism growth and development. Since, the main function of ALB is to maintain osmotic pressure in vascular and form the binding protein for material transport, the significantly higher rate of ALB/TP in animals from group C could be used to indicate TF effectiveness in improving animal growth.
TF was traditionally regarded as activators of the cell-mediated immune system and had no significant effects on the B cell-mediated immune function (Alvarez-Thull and Kirpatrick, 1996). In this study we found out that TF could regulate the status of immunity. The significantly higher antibody titre and wider fluctuation range of serum GLOB content helped the animals received TF treatment to cope with the CPV infection. Although, the immunologic mechanisms underlying the antigen-specific humoral immune effects of TF remain unknown, our observations established beyond doubt the efficacy of specific TF preparations in preventing CPV infection and animals can benefit from these marked improvements.
The high fatality rate of CPV has led to a variety of attempts to improve survival by boosting the body's immune defenses in the prevention and control of this disease. A controlled study using TF with specific activity against CPV was thus carried out and demonstrated that antigen-specific TF was efficacious in enhancing the immune response of the organism.
This study was financially supported by grants from Key Discipline of Genetic Breeding from Jiangsu Province, Peoples Republic of China.
1: Alvarez-Thull, L. and C.H. Kirkpatrick, 1996. Profiles of cytokine production in recipients of transfer factors. Biotherapy, 9: 55-59.
2: Appel, M.J., F.W. Scott and L.E. Carmichael, 1979. Isolation and immunization studies of a canine parvo-like virus from dogs with hemorrhagic enteritis. Vet. Rec., 105: 156-159.
3: Byston J., K. Cech, J. Pekarek and J. Jilkova, 1996. Effect of anti-herpes specific transfer factor. Biotherapy, 9: 73-75.
4: Corbeel, L., J.L. Ceuppens, G. van den Berghe, H. Claeys and M.D. Casteels-Van, 1984. Immunological observations before and after successful treatment of chronic mucocutaneous candidiasis with ketoconazole and transfer factor. Eur. J. Pediatr., 143: 45-48.
5: Dvoroznakova, E., J. Porubcova and Z. Sevcikova, 2009. Immune response of mice with alveolar echinococcosis to therapy with transfer factor, alone and in combination with albendazole. Parasitol Res., 105: 1067-1076.
6: Fujisawa, T., Y. Yamaguchi, H. Kimura, M. Arita, M. Shiba and M. Baba, 1984. Randomized controlled trial of transfer factor immunochemotherapy as an adjunct to surgical treatment for primary adenocarcinoma of the lung. Jpn. J. Surg., 14: 452-458.
7: Ikeda, Y., K. Nakamura, T. Miyazawa, E. Takahashi and M. Mochizuki, 2002. Feline host range of canine parvovirus: Recent emergence of new antigenic types in cats. Emerg. Infect. Dis., 8: 341-346.
8: Kirkpatrick, C.H., 1996. Activities and characteristics of transfer factors. Biotherapy, 9: 13-16.
9: Levine, P.H., 1996. The use of transfer factors in chronic fatigue syndrome: Prospects and problems. Biotherapy, 9: 77-79.
10: Martella, V., A. Cavalli, A. Pratelli, G. Bozzo and M. Camero et al., 2004. A canine parvovirus mutant is spreading in Italy. J. Clin. Microbiol., 42: 1333-1336.
11: Mathys, A., R. Mueller, N.C. Pedersen and G.H. Theilen, 1983. Hemagglutination with formalinfixed erythrocytes for detection of canine parvovirus. Am. J. Vet. Res., 44: 150-151.
12: Neequaye, J., D. Viza, G. Pizza, P.H. Levine and C. De Vinci et al., 1990. Specific transfer factor with activity against Epstein-Barr virus reduces late relapse in endemic Burkitt's lymphoma. Anticancer Res., 10: 1183-1187.
13: Ohshima, T., M. Kishi and M. Mochizuki, 2004. Sequence analysis of an Asian isolate of minute virus of canines. Virus Genes, 29: 291-296.
14: Parrish, C.R., P.H. O'Connell, J.F. Evermann and L.E. Carmichael, 1985. Natural variation of canine parvovirus. Science, 230: 1046-1048.
15: Parrish, C.R., P. Have, W.J. Foreyt, J.F. Evermann, M. Senda and L.E. Carmichael, 1988. The global spread and replacement of canine parvovirus. J. Gen. Virol., 69: 1111-1116.
16: Pizza, G., D. Viza, C. De Vinci, A. Palareti, D. Cuzzocrea, V. Fornarola and R. Baricordi, 1996. Orally administered HSV-specific transfer factor (TF) prevents genital or labial herpes relapses. Biotherapy, 9: 67-72.
17: Pizza, G., F. Chiodo, V. Colangeli, F. Gritti, E. Raise, H.H. Fudenberg, C. De Vinci and D. Viza, 1996. Preliminary observations using HIV-specific transfer factor in AIDS. Biotherapy, 9: 41-47.
18: Pizza, G., R. Meduri, C. De Vinci, L. Scorolli and D. Viza, 1994. Transfer factor prevents relapses in herpes keratitis patients: A pilot study. Biotherapy, 8: 63-68.
19: Prasad, U., M.A.B. Jalaludin, P. Rajadurai, G. Pizza, C. De Vinci, D. Viza and P.H. Levine, 1996. Transfer factor with anti-EBV activity as an adjuvant therapy for nasopharyngeal carcinoma: A pilot study. Biotherapy, 9: 109-115.
20: Tarkkanen, J., P. Grohn, E. Heinonen, O. Alfthan and S. Pyrhonen, 1981. Transfer factor immunotherapy of recurrent non-infiltrative papillary bladder tumours. Cancer Immunol. Immunother., 10: 251-255.
CrossRef | Direct Link |
21: Truyen, U., 2006. Evolution of canine parvovirus: A need for new vaccines? Vet. Microbiol., 117: 9-13.
CrossRef | PubMed |
22: Truyen, U., 1999. Emergence and recent evolution of canine parvovirus. Vet. Microbiol., 69: 47-50.
23: Vera, S.B., L. Le Cam, A.S. Levin, J.O. Johnston and A.J. Hackett, 1979. Immunotherapy of osteogenic sarcoma with transfer factor. Cancer Immunol. Immunother., 6: 243-253.
CrossRef | Direct Link |